Lentinan and Inflammatory Cytokine Modulation

Shiitake Mushrooms

Selective: lentinan blocks inflammasomes while maintaining pro-inflammatory cytokines

Ahn and colleagues found that lentinan selectively attenuates AIM2 and non-canonical inflammasome activation while simultaneously inducing pro-inflammatory cytokine production. This means lentinan is not a general anti-inflammatory: it specifically blocks the runaway inflammatory pathways while preserving the immune system's ability to fight pathogens.

Ahn et al., Scientific Reports, 2017

AIM2 inflammasome

a sensor complex associated with autoimmune conditions, IBD, and cancer-promoting chronic inflammation; specifically attenuated by lentinan (Ahn et al., 2017)

IL-13 + CD30L

inflammatory cytokines reduced by lentinan in IBD mouse models while therapeutic effects on colitis were documented (Liu et al., 2019)

TLR4/Dectin-1

the primary pattern recognition receptors activated by lentinan, triggering MAPK, Syk-PKC-NFkB, and JAK/STAT pathways (Zhou et al., 2024)

Ahn et al., Scientific Reports, 2017

View as image ↗

Most coverage of lentinan's immune effects treats it as an anti-inflammatory or an immune stimulant, depending on which study is being cited. Both framings are partly correct and both miss the deeper point: lentinan is an immunomodulator that selectively targets specific inflammatory pathways while leaving others intact.

The most counterintuitive finding in lentinan research, and the one most absent from consumer content, comes from Ahn and colleagues' 2017 study: lentinan selectively attenuates AIM2 and non-canonical inflammasomes while simultaneously inducing pro-inflammatory cytokine production.^[1] In plain language: lentinan blocks the inflammatory circuits that drive chronic pathological inflammation while keeping the ones that fight infections intact. This selective modulation is what makes lentinan clinically useful for conditions like IBD and cancer without broadly immunosuppressing patients.

For the clinical evidence on lentinan combined with chemotherapy, see lentinan and chemotherapy: synergistic effects on survival. For the broader shiitake overview, see what is shiitake mushroom: the culinary mushroom with medicinal power.

Key Takeaways

Lentinan selectively attenuates AIM2 and non-canonical inflammasome activation while inducing pro-inflammatory cytokine production, making it an immunomodulator rather than a simple anti-inflammatory (Ahn et al., Scientific Reports, 2017)
AIM2 inflammasomes are sensor complexes associated with autoimmune conditions, inflammatory bowel disease progression, and cancer-promoting chronic inflammation; their selective attenuation by lentinan explains its therapeutic profile in these conditions
Liu et al. (2019) documented lentinan's therapeutic effects in IBD models, including reduction of IL-13 and CD30L cytokines that drive intestinal inflammation while showing therapeutic effects on colitis and colitis-associated cancer in mice
Zhou et al.'s 2024 comprehensive review mapped lentinan's complete signaling pathway: TLR4/Dectin-1 activation → MAPK cascade; Syk-PKC-NFkB pathway; JAK/STAT modulation, establishing the molecular architecture behind its immunomodulatory effects
The selective nature of lentinan's immunomodulation is clinically important: patients receiving lentinan alongside chemotherapy maintain immune defense against infections while the pathological inflammatory circuits are suppressed
Gaullier et al. (2011) RCT with soluble beta-glucan from shiitake mycelium in healthy elderly subjects provided clinical context for how shiitake-derived beta-glucan affects cytokine profiles in living people
The core mechanistic evidence (Ahn 2017; Liu 2019) is preclinical — mouse macrophages and mouse disease models — so the selectivity is a well-characterized mechanism rather than proven human efficacy

One Molecule, Two Opposite Effects

Selective, Not Suppressive: What Lentinan Turns Down vs. Keeps On

A blanket anti-inflammatory lowers every inflammatory circuit at once, which is why chronic use impairs immune defense. Lentinan does the opposite: it dampens the AIM2 and non-canonical inflammasomes that drive pathological inflammation while preserving — even inducing — the pro-inflammatory circuits that fight pathogens and tumors. Reading the two lanes side by side is the fastest way to see why "immunomodulator" fits lentinan better than "anti-inflammatory."

Dampened — pathological circuits

AIM2 + non-canonical inflammasomes turned down

These sensor complexes detect cytosolic DNA and LPS. When chronically over-activated they drive the sterile inflammation behind IBD, autoimmunity, and cancer-promoting tissue damage. Lentinan selectively attenuates them — in macrophages, dose-dependent falls in caspase-1, IL-1beta and IL-18.

Ahn 2017 [1] (murine BMDMs + mouse challenge) · Liu 2019 [2] (↓IL-13, ↓CD30L in mouse IBD/colitis models)

Preserved — defensive circuits

Canonical NLRP3/NLRC4 + pro-inflammatory cytokines kept intact

Lentinan did not suppress the canonical NLRP3 or NLRC4 inflammasomes, and it simultaneously increased TLR4-primed pro-inflammatory cytokine production. These are the circuits that fight infection and prime anti-tumor immunity — so they stay online rather than being switched off.

Ahn 2017 [1] (NLRP3/NLRC4 unaffected; TLR4 priming ↑) · Zhou 2024 [3] (TLR4/Dectin-1 → MAPK, Syk-PKC-NFkB, JAK/STAT)

Every step shown is from preclinical work: Ahn 2017 [1] in mouse bone-marrow-derived macrophages and mouse challenge models, and Liu 2019 [2] in mouse IBD and colitis-associated-cancer models. This is a mechanistic selectivity signal, not human efficacy evidence. The one human study in this article — Gaullier 2011, a crossover trial of shiitake-mycelium beta-glucan in healthy elderly — did not test the inflammasome pathway.

Mechanism synthesis; lanes from refs [1][2][3] (see references)

Immunomodulator vs. Anti-Inflammatory: Why the Distinction Matters

How lentinan's inflammatory effect is usually described

The single most common framing gets the mechanism backwards

The claim

“Lentinan is an anti-inflammatory — it lowers inflammation, so it calms the immune system the way an anti-inflammatory drug does.”

Consumer wellness content that sorts every compound into either 'immune booster' or 'anti-inflammatory,' with no category for a compound that does both selectively.

What research shows

Misleading

In macrophage and mouse models, lentinan selectively attenuates the AIM2 and non-canonical inflammasomes that drive pathological chronic inflammation while simultaneously inducing pro-inflammatory cytokine production — the opposite of what a blanket anti-inflammatory does.

This selectivity is exactly why lentinan can be used alongside cancer therapy without broadly immunosuppressing patients. Calling it 'anti-inflammatory' predicts the wrong clinical behavior. The finding is preclinical (cell and mouse), so 'immunomodulator' describes a documented mechanism, not a proven human outcome.

Ahn et al., Scientific Reports, 2017 [ref 1]

The words "anti-inflammatory" and "immunomodulator" sound similar but describe very different mechanisms with very different clinical implications.

A pure anti-inflammatory suppresses inflammatory signaling broadly, reducing the immune response across multiple pathways. This is useful for acute inflammation reduction but problematic in chronic use because it simultaneously impairs the immune system's ability to fight infections and eliminate cancer cells.

An immunomodulator selectively adjusts which inflammatory pathways are active, reducing pathological inflammation while preserving or even enhancing beneficial immune functions. This is the profile you want for conditions where chronic inflammation is part of the disease mechanism: inflammatory bowel disease, rheumatoid arthritis, and the tumor microenvironment where chronic inflammation actively promotes cancer progression.

Lentinan is an immunomodulator in this specific sense. Ahn's 2017 finding demonstrated this selectivity in precise mechanistic terms in mouse macrophages and mouse challenge models: lentinan specifically blocks AIM2 and non-canonical inflammasomes while simultaneously maintaining the pro-inflammatory cytokine production that defends against infections and tumors. It is important to be clear about what kind of evidence this is — a well-characterized cellular and animal mechanism, not a demonstration of efficacy in human patients.

The AIM2 Inflammasome: What Lentinan Is Specifically Blocking

AIM2 (Absent in Melanoma 2) is a cytosolic sensor that detects double-stranded DNA in the cell's interior, a signal of viral infection or cellular damage. When activated, AIM2 assembles an inflammasome complex that produces large amounts of IL-1beta and IL-18 and triggers inflammatory cell death (pyroptosis).

Under normal circumstances, AIM2 activation is protective: it signals that something has gone wrong inside the cell. But dysregulated AIM2 activation is associated with multiple pathological conditions including inflammatory bowel disease, autoimmune conditions, and the chronic sterile inflammation that promotes tumor progression.

Non-canonical inflammasomes are a related set of inflammatory sensor complexes (involving caspase-4, caspase-5 in humans) that respond to cytosolic LPS and other danger signals. Their excessive activation is similarly associated with inflammatory pathology.

Ahn and colleagues specifically tested which inflammasome pathways lentinan affects and found selective attenuation of AIM2 and non-canonical inflammasomes without affecting canonical NLRP3 inflammasome activation, which remains active for normal pathogen defense.^[1] This is precise molecular selectivity, not a general suppression.

Mechanistic study — mouse macrophages

Lentinan turned down AIM2 while leaving canonical inflammasomes — and pathogen defense — intact

Ahn et al. (2017) · Scientific Reports

Population: Mouse bone-marrow-derived macrophages (BMDMs) plus mouse challenge models
Intervention: Lentinan from shiitake, tested against distinct inflammasome-activating stimuli
Comparator: Untreated macrophages across canonical (NLRP3, NLRC4), AIM2, and non-canonical activation
Finding: Lentinan attenuated AIM2 and non-canonical inflammasome outputs — dsDNA-triggered caspase-1, IL-1beta and IL-18 fell in a dose-dependent way — while NLRP3 and NLRC4 readouts were not suppressed and TLR4-primed pro-inflammatory cytokine production actually increased. No cytotoxicity was seen across the tested macrophage range.

preliminary This is the mechanistic keystone of the whole 'selective immunomodulator' framing — but it is a cell and mouse study. It establishes how lentinan behaves at the molecular level, not that it treats any human condition.

Ahn et al., Scientific Reports, 2017 [ref 1], PMID 28465544

IBD and Cancer: How This Selectivity Plays Out in Disease Models

Liu and colleagues (2019) ran an experimental study of lentinan in mouse models of inflammatory bowel disease and colitis-associated cancer, using dextran-sulfate-sodium (DSS)- and TNBS-induced colitis and an azoxymethane/DSS cancer model.^[2] The findings demonstrated measurable therapeutic effects in these animal models:

In IBD models, lentinan reduced levels of IL-13 and CD30L, two cytokines that drive intestinal epithelial damage and immune dysregulation in colitis. IL-13 promotes Th2-type inflammation that impairs gut barrier function; CD30L is involved in T cell-mediated intestinal damage. Reducing these specific cytokines while leaving other immune functions intact is consistent with the selective immunomodulation profile documented by Ahn.

In colitis-associated cancer models, lentinan's suppression of chronic inflammation (which drives malignant transformation in repeatedly inflamed tissue) provided a protective effect against tumor development. This is the inflammasome-suppression mechanism in disease-relevant context: chronic AIM2 and non-canonical inflammasome activation in inflamed intestinal tissue promotes the sequential inflammation-dysplasia-carcinoma progression; lentinan's selective attenuation of this pathway has downstream protective effects.

The Complete Signaling Map: How Lentinan Talks to Cells

Zhou and colleagues (2024) published a comprehensive review of lentinan's progress in inflammatory and tumor diseases that mapped the complete molecular signaling architecture for how lentinan interacts with cells.^[3]

Primary receptor activation: Lentinan binds TLR4 (Toll-like receptor 4) and Dectin-1 (a beta-glucan receptor) on immune cell surfaces. These are the entry points for the downstream signaling cascades.

MAPK cascade: TLR4/Dectin-1 activation triggers mitogen-activated protein kinase phosphorylation, including ERK, JNK, and p38 MAPK. This cascade regulates transcription of cytokine genes, explaining both the pro-inflammatory cytokine induction and the anti-inflammatory effects depending on which MAPK branch is activated.

Syk-PKC-NFkB pathway: Dectin-1 signaling specifically activates Syk kinase and protein kinase C, which activate NFkB transcription factor. NFkB drives expression of multiple pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-12), the pathway that lentinan activates for anti-tumor immune response, while simultaneously, through other branches, modulating the inflammasome pathways.

JAK/STAT pathway: Janus kinase and signal transducer and activator of transcription signaling mediates cytokine receptor responses and affects T cell polarization. Lentinan's effects on JAK/STAT contribute to its Th1-promoting activity.

This signaling complexity is why lentinan's effects are selective rather than simple: different receptor pathways, different downstream cascades, and different transcriptional outcomes produce the sophisticated immunomodulatory profile rather than a simple on/off switch for inflammation.

Clinical Evidence: Beta-Glucan from Shiitake Mycelium in Elderly Subjects

Gaullier and colleagues (2011) conducted a crossover, placebo-controlled clinical trial of soluble beta-glucan from shiitake mycelium (Lentinus edodes mycelium extract) in healthy elderly subjects.^[4]

Elderly subjects are a relevant clinical population for beta-glucan immune effects because aging is associated with immunosenescence (progressive immune dysfunction) and increased baseline inflammatory signaling. The study found measurable effects on immune cell populations and cytokine profiles in the beta-glucan group compared to placebo.

The study used mycelium extract rather than the injectable lentinan used in cancer trials, representing a form more similar to what oral supplements provide. This provides clinical context for how shiitake-derived beta-glucan affects immune parameters in living people, a closer translation to the supplement use case than most lentinan research, which focuses on injectable pharmaceutical-grade compound.

Evidence quality — lentinan's selective cytokine/inflammasome modulation

Where the 'selective immunomodulator' claim actually sits on the research ladder

Cell & Lab Studiescompleted
Ahn 2017 [1] in mouse macrophages: selective attenuation of AIM2 and non-canonical inflammasomes (↓caspase-1, IL-1beta, IL-18) with NLRP3/NLRC4 preserved and TLR4 priming increased. Zhou 2024 [3] maps the TLR4/Dectin-1 → MAPK, Syk-PKC-NFkB, JAK/STAT signaling architecture.
Animal Studiescompleted
Liu 2019 [2]: lentinan reduced IL-13 and CD30L and improved disease activity in mouse DSS/TNBS colitis and AOM/DSS colitis-associated-cancer models, outperforming sulfasalazine at high dose.
Case Reports & Early Seriesmissing
No case series isolate the inflammasome/cytokine-selectivity endpoint in humans; human lentinan use has centered on cancer survival, not IBD or autoimmune inflammation.
Small Human Trialscurrent
Gaullier 2011 [4], a crossover placebo-controlled trial of shiitake-mycelium beta-glucan in healthy elderly, is the closest human data — but it measured general immune/cytokine parameters in a healthy population, not AIM2/non-canonical inflammasome activity in disease.
Large Randomized Trialsmissing
No large RCT has tested lentinan specifically for the inflammasome-driven inflammation of IBD, autoimmunity, or the tumor microenvironment.
Meta-Analyses & Systematic Reviewsmissing
Meta-analytic support exists for lentinan as a cancer chemotherapy adjuvant, but not for the selective anti-inflammasome mechanism described here.

The selectivity mechanism is well-characterized in cells and mouse disease models and has a molecular map, but the human evidence is a single small trial in healthy elderly using a beta-glucan supplement — not a disease trial of the inflammasome endpoint. Treat the selective-immunomodulator profile as a strong mechanistic hypothesis, not an established human treatment effect.

Ahn 2017 [1]; Liu 2019 [2]; Zhou 2024 [3]; Gaullier 2011 [4]

The Clinical Relevance of Selective Immunomodulation

The clinical value of lentinan's selectivity becomes clear when you consider what diseases share the profile of pathological inflammasome overactivation alongside impaired immune defense:

Inflammatory bowel disease involves both chronic inflammation (driven in part by excessive inflammasome activation in the intestinal epithelium) and impaired immune barrier function. Lentinan's profile of blocking AIM2 and non-canonical inflammasomes while maintaining pro-inflammatory cytokine production addresses both aspects simultaneously.

Cancer immunity requires maintaining T cell and NK cell activity (which lentinan supports through Th1 and ADCC enhancement) while blocking the chronic tumor microenvironment inflammation that promotes tumor progression (which lentinan addresses through selective inflammasome attenuation).

Autoimmune modulation benefits from selectively reducing the pathological inflammatory pathways (inappropriate AIM2 activation against self-antigens) while preserving protective immunity.

Lentinan's selectivity is not just a mechanistic curiosity; it is the feature that makes it clinically useful in these conditions without producing the immunosuppression that broad anti-inflammatory drugs cause.

How to read this evidence

Moderate

This is mechanism research, not medical advice — and the studied form is not a supplement

Concern

The clinical lentinan in cancer research is a purified, pharmaceutical-grade compound given by injection under medical supervision. Most of the inflammasome-selectivity evidence here comes from cell and mouse studies. Over-the-counter shiitake or beta-glucan supplements are a different preparation, at different doses, by a different route, and have not been shown to reproduce these effects in people with IBD, autoimmune disease, or cancer.

What the research says

Read the selective-immunomodulator profile as a well-characterized mechanism and a research direction, not as a validated treatment you can self-administer with a supplement.

Particularly relevant for: Anyone with an autoimmune or inflammatory condition, an active cancer diagnosis, or on immune-modulating medication

What to do

Do not use lentinan or beta-glucan products to treat or replace therapy for any medical condition without first consulting your physician, who can weigh interactions with immune-active treatments.

Ahn et al., 2017 [ref 1]; Gaullier et al., 2011 [ref 4]

The Bottom Line

Lentinan is a selective immunomodulator that attenuates AIM2 and non-canonical inflammasome activation while inducing pro-inflammatory cytokines (Ahn et al., 2017), making it mechanistically distinct from broad anti-inflammatory compounds. Zhou et al.'s 2024 comprehensive review mapped the complete signaling architecture: TLR4/Dectin-1 activation triggers MAPK, Syk-PKC-NFkB, and JAK/STAT pathways that collectively produce the selective inflammatory modulation. In IBD models, lentinan reduced IL-13 and CD30L while showing therapeutic effects on colitis and colitis-associated cancer (Liu et al., 2019). Gaullier et al. (2011) documented cytokine effects from shiitake-derived beta-glucan supplementation in healthy elderly subjects.

Frequently Asked Questions

Lentinan is a beta-1,3-glucan polysaccharide from shiitake mushroom (Lentinus edodes) with selective immunomodulatory activity. It is not a general anti-inflammatory: it specifically attenuates AIM2 and non-canonical inflammasomes (the sensor complexes associated with pathological chronic inflammation in conditions like IBD and cancer) while simultaneously inducing pro-inflammatory cytokines that maintain immune defense. This selectivity is what makes it useful as an immune adjuvant without causing broad immunosuppression.

Lentinan's effects on specific cytokines depend on the cellular context and pathway. Its NFkB activation through Dectin-1/Syk-PKC induces pro-inflammatory cytokines including TNF-alpha and IL-12, which are part of its anti-tumor immune activation mechanism. Simultaneously, through MAPK pathway activity, it suppresses certain inflammatory mediators and inflammasome-driven cytokines. The net effect is selective modulation rather than simple reduction of TNF-alpha and IL-6, which is why lentinan's effects vary by disease context.

Through multiple receptor pathways: TLR4 and Dectin-1 binding activates three downstream cascades (MAPK, Syk-PKC-NFkB, and JAK/STAT) that collectively regulate cytokine production, T cell polarization, and inflammasome activity (Zhou et al., 2024). Key effects include Th1 immune response enhancement, NK cell activation, CD8+ T cell priming, selective AIM2 and non-canonical inflammasome attenuation, and reduction of specific cytokines driving pathological inflammation (IL-13, CD30L in IBD contexts).

Yes and no, depending on which inflammatory pathway. Lentinan selectively blocks AIM2 and non-canonical inflammasomes (anti-inflammatory for pathological chronic inflammation) while simultaneously activating NFkB-driven pro-inflammatory cytokine production that maintains immune defense. This selective profile is why "immunomodulator" describes lentinan more accurately than "anti-inflammatory." The distinction matters clinically: pure anti-inflammatories impair immune defense; selective immunomodulators address pathological inflammation while preserving it.

Lentinan reduces IL-13 and CD30L in IBD models (Liu et al., 2019) and attenuates AIM2 and non-canonical inflammasome-driven cytokines (Ahn et al., 2017). It induces pro-inflammatory cytokines including IL-12 and TNF-alpha through NFkB pathway activation, which contributes to its anti-tumor immune activation. It shifts the Th1/Th2 balance toward Th1 (anti-tumor, anti-pathogen) and activates IFN-gamma production. The net cytokine profile is context-dependent: lentinan enhances anti-tumor and anti-pathogen cytokines while suppressing the chronic sterile inflammation cytokines associated with IBD and tumor microenvironment promotion.

Sources & References

1RTHM-00459·Ahn, Huijeong et al. (2017). “Lentinan from shiitake selectively attenuates AIM2 and non-canonical inflammasome activation while inducing pro-inflammatory cytokine production..” Scientific reports.Study breakdown →PubMed →↩
2RTHM-01100·Liu, Yanrong et al. (2019). “Therapeutic effects of lentinan on inflammatory bowel disease and colitis-associated cancer..” Journal of cellular and molecular medicine.Study breakdown →PubMed →↩
3RTHM-02042·Zhou, Guangda et al. (2024). “Lentinan progress in inflammatory diseases and tumor diseases..” European journal of medical research.Study breakdown →PubMed →↩
4RTHM-00394·Gaullier, Jean-Michel et al. (2011). “Supplementation with a soluble β-glucan exported from Shiitake medicinal mushroom, Lentinus edodes (Berk.) singer mycelium: a crossover, placebo-controlled study in healthy elderly..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩